摘要
目的：阐明阿霉素（doxorubicin，ADM）对骨肉瘤细胞系MG63，骨肉瘤耐药细胞系MG63/DOX,以及原代培养骨肉瘤耐药细胞系GSF-0686细胞体外增殖抑制作用和多药耐药蛋白MRP4在细胞耐药中的作用。
方法：1）CCK-8法检测ADM对MG63，MG63/DOX，GSF-0686细胞的增殖抑制作用。2）5μmol ADM分别作用于MG63，MG63/DOX，SF-0686三株细胞后，使用液相色谱-串联质谱法测定不同时间点三种细胞内外的ADM药物浓度。3）Western Blotting法与qPCR法检测、比较三种细胞株的MRP4的表达。4）加ADM刺激MG63和MG63/DOX细胞后，采用qPCR法分别检测两种细胞随加药时间和药物浓度变化时肿瘤耐药相关蛋白MRP4基因的表达。
结果：1）ADM对MG63，MG63/DOX，GSF-0686的增殖均有抑制作用，但其对MG63/DOX和GSF-0686细胞的增殖抑制作用明显弱于MG63，有显著性差异（P＜0.05）。2）MG63/DOX和SF-0686细胞内ADM浓度明显低于MG63细胞内浓度，同时MG63/DOX和SF-0686细胞外ADM浓度明显高于MG63细胞外浓度。3）耐药细胞株MG63/DOX和SF-0686中MRP4的mRNA与蛋白表达量均高于亲本株MG63。4）ADM可下调MG63/DOX和MG63细胞MRP4的mRNA，但在耐药株中其下调作用弱于亲本株，差异均有统计学意义（p<0.05）。
结论：（1）ADM对MG63/DOX和GSF-0686增殖的抑制作用较弱；（2）MG63/DOX细胞和SF-0686细胞对ADM耐药。3)MRP4可能通过表达上调促进细胞内药物外排参与MG63/DOX和SF-0686的耐药作用。
Objective: To investigate the effects of doxorubicin (ADM) on proliferation ofosteosarcoma cell MG63, osteosarcoma multidrug resistant cell MG63/DOX, andprimary osteosarcoma resistant cell SF-0686, and the effect of multidrug resistanceprotein MRP4on drug resistant cells.
Methods:1)CCK-8assay was used to investigate the proliferation of MG63,MG63/DOX and GSF-0686cells,2) The concentration of ADM in cells andextracellular fluid were detected at different time points after given the ADM withliquid chromatography-tandem mass spectrometry (LC/MS/MS).3)WesternBlotting and RT-PCR were used to detect the protein and gene expression of MRP4ofMG63, MG63/DOX and GSF-0686cells.y4)After given ADM, the gene expressionof MRP4was detected with time and the concentration using qPCR.
Results:1)ADM inhibited the proliferation of MG63, MG63/DOX and GSF-0686cells, and the inhibitory effect on MG63/DOX and GSF-0686was lower than that onMG63(p＜0.05).2) The concentration of ADM in MG63/DOX and GSF-0686cellswas lower compared with MG63, and the concentration of extracellular fluid inMG63/DOX and GSF-0686cells was higher than that in MG63.3) The protein andgene expression of MRP4of MG63/DOX and GSF-0686cells were higher comparedwith MG63.4) The mRNA and protein expression of MG63/DOX and MG63cellswere down regulated after using ADM, but the effect on MG63was higher(p＜0.05).
Conclusion:(1) The inhibitory effect of ADM on the proliferation of MG63/DOXand GSF-0686cells was weak,(2) MG63/DOX and SF-0686cells were resistant toADM,(3) multi-drug resistance associated protein MRP4plays an important role inmultidrug resistance of osteosarcoma.
引文
[1]HEARE T, HENSLEY M A, DELL'ORFANO S. Bone tumors: osteosarcoma and Ewing's sarcoma [J]. Curr Opin Pediatr,2009,21(3):365-72.
[2]LEE J A, KIM M S, KIM D H, et al. Osteosarcoma developed in the period of maximal growth rate have inferior prognosis [J]. J Pediatr Hematol Oncol,2008,30(6):419-24.
[3]WU P K, CHEN W M, CHEN C F, et al. Primary osteogenic sarcoma with pulmonary metastasis:clinical results and prognostic factors in91patients [J]. Jpn J Clin Oncol,2009,39(8):514-22.
[4]牛晓辉.骨肉瘤的综合治疗[M].第九届全国骨肿瘤学术会议论文集.2007.
[5]NADKAR A, PUNGALIYA C, DRAKE K, et al. Therapeutic resistance in lung cancer [J]. Expert Opin Drug Metab Toxicol,2006,2(5):753-77.
[6]FREDERICK C A, WILLIAMS L D, UGHETTO G, et al. Structural comparison of anticancer drug-DNA complexes:adriamycin and daunomycin [J]. Biochemistry,1990,29(10):2538-49.
[7]Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development [J]. Curr Med Chem,2008,15(20):1981-2039.
[8]Role of multidrug resistance associated proteins in drug development [J]. Drug Discov Ther,2008,2(6):305-32.
[9]ZHOU S F, WANG L L, DI Y M, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development [J]. Curr Med Chem,2008,15(20):1981-2039.
[10]YANG A K, ZHOU Z W, WEI M Q, et al. Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases [J]. Curr Top Med Chem,2010,10(17):1732-56.
[11]ABC multidrug transporters:target for modulation of drug pharmacokinetics and drug-drug interactions [J]. Curr Drug Targets,2011,12(5):600-20.
[12]Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases [J]. Curr Top Med Chem,2010,10(17):1732-56.
[13]Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases [J]. FEBS J,2011,278(18):3226-45. doi:10.1111/j.742-4658.2011.08235.x. Epub2011Aug1.
[14]TAKESHITA H, KUSUZAKI K, MURATA H, et al. Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model [J]. Br J Cancer,2000,82(7):1327-31.
[15]TSANG W P, HO F Y, FUNG K P, et al. p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis [J]. Int J Cancer,2005,114(3):331-6.
[16]CHANO T, MORI K, SCOTLANDI K, et al. Differentially expressed genes in multidrug resistant variants of U-2OS human osteosarcoma cells [J]. Oncol Rep,2004,11(6):1257-63.
[17]FERRARI S, MERCURI M, BACCI G Comment on "Prognostic factors in high-grade osteosarcoma of the extremities or trunk:an analysis of1,702patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols"[J]. J Clin Oncol,2002,20(12):2910; author reply-1.
[18]熊桑.吡柔比星对骨肉瘤多药耐药细胞系MG63/DOX体外增殖 抑制作用及其机制的研究[D],2011.
[19]熊绍权,龙奇达,林丽珠.骨肉瘤研究进展：2009年ASCO会议述评[J].肿瘤,2009,29(12)：3.
[20]Modulation of human multidrug resistance protein (MRP)1(ABCC1) and MRP2(ABCC2) transport activities by endogenous and exogenous glutathione-conjugated catechol metabolites [J]. Drug Metab Dispos,2008,36(3):552-60.
[21]Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2)[J]. Curr Top Med Chem,2009,9(2):130-47.
[22]Transport of the coumarin metabolite7-hydroxycoumarin glucuronide is mediated via multidrug resistance-associated proteins3and4[J]. Drug Metab Dispos,2012,40(6):1076-9.
[23]PR W, IV D H, G R, et al. Characterization of the MRP4-and MRP5-mediated transport of cyclic nucleotides from intact cells [J]. The Journal of Biological Chemistry,2003,278(20):8.
[24]M T, S K, H I, et al. MRP4knockdown enhances migration, suppresses apoptosis, and produces aggregated morphology in human retinal vascular endothelial cells [J]. Biochemical and Biophysical Research Communications,2010,400(4):6.
[25]The role of ABC transporters in drug resistance, metabolism and toxicity [J]. Curr Drug Deliv,2004,1(1):27-42.
[26]D S J, C C M, D S. MRP4:a previously unidentified factor in resistance to nucleoside-based antiviral drugs [J]. Nature Medicine,1999,5.
[27]HOELLEIN A, DECKER T, BOGNER C, et al. Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70status [J]. J Cancer Res Clin Oncol,2010,136(3):403-10.
[28]MORGAN J A, CHEEPALA S B, WANG Y, et al. Deregulated hepatic metabolism exacerbates impaired testosterone production in Mrp4-deficient mice [J]. The Journal of Biological Chemistry,2012,287(18):11.
[29]吴小三.人骨肉瘤细胞阿霉素耐药株MG63/ADR的建立及采用基因芯片技术对骨肉瘤耐药相关基因的初步研究[D],2010.
[30]ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in5-fluorouracil-resistant cells [J]. Pancreatology,2009,9(1-2):136-44.
[31]HUYNH T, NORRIS M D, HABER M, et al. ABCC4/MRP4:a MYCN-regulated transporter and potential therapeutic target in neuroblastoma [J]. Front Oncol,2012,2(178).
[32]柴瑞,于志奇,傅传刚,et al.多药耐药蛋白4与直肠癌放疗敏感性关系的初步研究[J].中华胃肠外科杂志,2011,14(8)：
[33]Mrp4Confers Resistance to Topotecan and Protects the Brain from Chemotherapy [J].2004,
[34]ZHANG Y H, WU Q, XIAO X Y, et al. Silencing MRP4by small interfering RNA reverses acquired DDP resistance of gastric cancer cell [J]. Cancer Lett,2010,291(1):76-82.
[35]JANKE D, MEHRALIVAND S, STRAND D, et al.6-mercaptopurine and9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two mis sense mutations in the drug transporter gene ABCC4[J]. Hum Mutat,2008,29(5):659-69.
[36]TIAN Q, ZHANG J, TAN T M, et al. Human multidrug resistance associated protein4confers resistance to camptothecins [J]. Pharm Res,2005,22(11):1837-53.
[37]Functional involvement of multidrug resistance-associated protein4(MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovirand tenofovir [J]. Mol Pharmacol,2007,71(2):619-27. Epub2006Nov
1da Gra a Rocha G, Sim es M, Oliveira RR,et al.Effects of3beta-Acethyl Tormentic Acid (3ATA) on ABCC Proteins Activity. Int JMol Sci,2012,13(6)757-771.
2Qi WX, He AN, Tang LN, et al. Efficacy and safety ofgemcitabine-docetaxel combination therapy for recurrent or refractoryhigh-grade osteosarcoma in China: a retrospective study of18patients.Jpn J Clin Oncol,2012,42(5)427-431.
3Min D, Lin F, Shen Z, et al. Analysis of prognostic factors in333Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy. Asia Pac J Clin Oncol,2012,10(11):743-756.
4孙大辉,张德宝,谷贵山,等.差异凝胶电泳筛选人骨肉瘤细胞多药耐药相关蛋白.中国肿瘤生物治疗杂志,2008,15(5)：440-443.
5DQbska S, Owecka A, Czernek U, et al.Transmembrane transporters ABCC-structure, function and role in multidrug resistance of cancer cells. Postepy Hig Med Dosw (Online),2011,65(5):52-61.
6Cantore M, Capparelli E, Berardi F, et al. Clinical pharmacokinetic and metabolism of PET radiotracers for imaging P-glycoprotein in chemoresistant tumor of colorectal cancer. Curr Drug Metab,2011,12(10):985-988.
7Yang AK, Zhou ZW, Wei MQ, et al. Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases. Curr Top Med Chem,2010,10(17):1732-1756.
8Bartosiewicz D, Krasowska A. Inhibitors of ABC transporters and biophysical methods to study their activity. Z Naturforsch C,2009,64(5-6):454-458.
9He SM, Li R, Kanwar JR, et al. Structural and functional properties of human multidrug resistance protein1(MRP1/ABCC1). Curr Med Chem,2011,18(3):439-481.
10Rau S, Autschbach F, Riedel HD, et al. Expression of the multidrug resistance proteins MRP2and MRP3in human cholangiocellular carcinomas. Eur J Clin Invest,2008,38(2):134-142.
11Cui Y, Konig J, Buchholz JK, et al. Drug resistance andATP-dependent conjugate transport mediated by the apical multidrugresistance protein, MRP2, permanently expressed in human and caninecells. Mol Pharmacol,1999,55(5)929-937.
12Chen ZS, Kawabe T, Ono M, et al. Effect of multidrugresistance-reversing agents on transporting activity of human canalicularmultispecific organic anion transporter. Mol Pharmacol,1999,56(6)1219-1228.
13Kruh GD, Belinsky MG, Gallo JM, et al. Physiological andpharmacological functions of Mrp2, Mrp3and Mrp4as determined fromrecent studies on gene-disrupted mice. Cancer Metastasis Rev,2007,26(1)5-14.
14Fukuda Y, Schuetz JD. ABC transporters and their role in nucleosideand nucleotide drug resistance. Biochem Pharmacol,2012,83(8)1073-1083.
15van de Ven R, de Groot J, Reurs AW, et al. Unimpaired immunefunctions in the absence of Mrp4(Abcc4). Immunology Letters,2009,124(2)81-87.
16Russel FG, Koenderink JB, Masereeuw R. Multidrug resistanceprotein4(MRP4/ABCC4): a versatile efflux transporter for drugs andsignalling molecules. Trends Pharmacol Sci,2008,29(4)200-207.
17Keppler D. Multidrug resistance proteins (MRPs, ABCCs): importancefor pathophysiology and drug therapy. Handb Exp Pharmacol,2011,20
1299-323.
18Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistanceproteins (MRPs). Essays Biochem,2011,50(1)179-207.
19Gradilone A, Pulcinelli FM, Lotti LV, et al. Celecoxib upregulates multidrug resistance proteins in colon cancer:lack of synergy with standard chemotherapy. Curr Cancer Drug Targets,2008,8(5):414-420.
20Chen ZS, Tiwari AK.Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J,2011,278(18):3226-3245.
21Plasschaert SL, de Bont ES, Boezen M, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res,2005,11(24):8661-8668.
22Oguri T, Ozasa H, Uemura T, et al. MRP7/ABCC10expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther,2008,7(5):1150-1155.
23代景莹,陈宝安.多药耐药相关蛋白7及其抑制剂.国际骨科学杂志,2010,37(11)：821-823
24Feng M, Zhou J, Wei L, et al.[Clinical significance of MRP8and cypA expression in laryngeal squamous cell carcinoma tissues]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,2011,25(18):834-836.
25Bessho Y, Oguri T, Ozasa H, et al. ABCC10/MRP7is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep,2009,21(1):263-268.
26曾恒,陈安民,李峰,等。骨肉瘤多药耐药表型的分化特性及矛盾相关性分析。中国骨伤,2008,21(5)：368-372.
27汪新媛,田京.骨肉瘤化疗研究进展.国际骨科学杂志,2010；31(3)：159-161.
28Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J,2011;278(18):3226-3245.
29Solazzo M, Fantappie O, Lasagna N, et al. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp Cell Res,2006,312(20):4070-4078.
30屠重棋,田永刚,裴福兴.多药耐药相关蛋白1在骨肉瘤中的表达.四川大学学报(医学版),2003；34(4)：605-609.
31Ito K, Fujimori M, Nakata S, et al. Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. Oncol Res,1998,10(2):99-109.
32Hoffmann J, Schmidt-Peter P, Hansch W, et al. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin Cancer Res,1999,5(8):2198-2204.